US20110020412A1 - Novel dosage and formulation - Google Patents

Novel dosage and formulation Download PDF

Info

Publication number
US20110020412A1
US20110020412A1 US12/921,921 US92192109A US2011020412A1 US 20110020412 A1 US20110020412 A1 US 20110020412A1 US 92192109 A US92192109 A US 92192109A US 2011020412 A1 US2011020412 A1 US 2011020412A1
Authority
US
United States
Prior art keywords
aclidinium
dose
pharmaceutical composition
micrograms
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/921,921
Other languages
English (en)
Inventor
Rosa Lamarca Casado
Gonzalo De Miquel Serra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39645012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110020412(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall SA filed Critical Almirall SA
Assigned to ALMIRALL, S.A. reassignment ALMIRALL, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAMARCA CASADO, ROSA, DE MIQUEL SERRA, GONZALO
Publication of US20110020412A1 publication Critical patent/US20110020412A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • This invention relates to a novel dosage for aclidinium and to novel methods and formulations for the treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD), using aclidinium.
  • respiratory diseases especially asthma and chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • Aclidinium bromide is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, described in, e.g., WO 0104118.
  • aclidinium is most effective upon administration by inhalation in a dosage of about 400 ⁇ g metered nominal dose, typically a single dosage of about 400 micrograms per day metered nominal dose, (e.g., about 360 ⁇ g emitted dose, and about 120 ⁇ g Fine Particle dose) (weight corresponding to aclidinium bromide).
  • the invention thus provides in a first embodiment a pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt, e.g., aclidinium bromide, in admixture with a pharmaceutically acceptable dry powder carrier, e.g., lactose particles, (i) comprising a single metered nominal dose of aclidinium equivalent to about 400 ⁇ g aclidinium bromide, or (ii) in a multidose dry powder inhaler device calibrated to provide a metered nominal dose of aclidinium equivalent to about 400 ⁇ g aclidinium bromide.
  • This composition can be administered one or more times per day. Preferably once or twice a day.
  • the invention provides a method of treating a respiratory condition, e.g., selected from asthma and chronic obstructive pulmonary disease, in a patient in need of such treatment, comprising administering a dose, typically a single daily dose or twice daily dose, of aclidinium, e.g., aclidinium bromide, equivalent to about 400 ⁇ g metered nominal dose aclidinium bromide, e.g., comprising administering a pharmaceutical composition according to the previous paragraph.
  • aclidinium e.g., aclidinium bromide
  • the invention further provides the use of aclidinium in the manufacture of a medicament, e.g., as described in the preceding paragraph, for use in such a method.
  • the aclidinium may be administered as monotherapy, or in combination with one or more additional anti-inflammatory and/or bronchodilating agents, e.g., corticosteroids, PDE IV inhibitors and ⁇ 2-agonists, e.g., formoterol, salmeterol, budesonide, and mometasone, and the invention thus further provides methods as described above further comprising administration of an effective amount of such an agent, as well as pharmaceutical compositions as described above, further comprising such additional agent(s).
  • additional anti-inflammatory and/or bronchodilating agents e.g., corticosteroids, PDE IV inhibitors and ⁇ 2-agonists, e.g., formoterol, salmeterol, budesonide, and mometasone
  • the aclidinium is administered in the form of a salt with an anion X, wherein X is a pharmaceutically acceptable anion of a mono or polyvalent acid. More typically, X is an anion derived from an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid, or an organic acid such as methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid or maleic acid.
  • X is an anion derived from an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid, or an organic acid such as methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid or maleic acid.
  • the aclidinium is in the form of aclidinium bromide.
  • the aclidinium is preferably administered in the form of a dry powder, in admixture with a suitable carrier, e.g., lactose powder, suitable for inhalation.
  • a suitable carrier e.g., lactose powder
  • the aclidinium is aclidinium bromide in admixture with lactose powder.
  • the respiratory disease or condition to be treated with the formulations and methods of the present invention is typically asthma, acute or chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), bronchial hyperreactivity or rhinitis, in particular asthma or chronic obstructive pulmonary disease (COPD), especially COPD.
  • COPD chronic obstructive pulmonary disease
  • “about” as used herein means within the normal limits of acceptable variations as defined by the European and US Pharmacopeia of plus/minus 35% or preferably acceptable variations as defined by the current most stringent requirement, the US FDA draft guidance for inhaler of plus/minus 25% or especially within the metered dosing accuracy for the dispensing system e.g. +/ ⁇ 10%
  • a metered nominal dose of “about 400 ⁇ g” is meant a target dose of 400 ⁇ g subject to variation within the normal limits of acceptance for the dispensing system, e.g.
  • the emitted dose and the fine particle dose are subjected to the same variation and proportional to the metered dose and are therefore for the emitted dose e.g. a metered nominal dose of about 400 ⁇ g (plus/minus 35%) corresponds to about 360 ⁇ g emitted dose (plus/minus 35%), and about 120 micrograms Fine Particle dose (plus/minus 35%)
  • Packaging of the formulation may be suitable for unit dose or multi-dose delivery.
  • the formulation can be pre-metered or metered in use. Dry powder inhalers are thus classified into three groups: (a) single dose, (b) multiple unit dose and (c) multi dose devices.
  • Formulations generally contain a powder mix for inhalation of the compounds of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred.
  • a suitable powder base such as lactose or starch. Use of lactose is preferred.
  • Each capsule or cartridge may generally contain between 2 ⁇ g and 400 ⁇ g of each therapeutically active ingredient. Alternatively, the active ingredient (s) may be presented without excipients.
  • single dose inhalers of the first type single doses have been weighed by the manufacturer into small containers, which are mostly hard gelatine capsules.
  • a capsule has to be taken from a separate box or container and inserted into a receptacle area of the inhaler.
  • the capsule has to be opened or perforated with pins or cutting blades in order to allow part of the inspiratory air stream to pass through the capsule for powder entrainment or to discharge the powder from the capsule through these perforations by means of centrifugal force during inhalation.
  • the emptied capsule has to be removed from the inhaler again.
  • disassembling of the inhaler is necessary for inserting and removing the capsule, which is an operation that can be difficult and burdensome for some patients.
  • Some capsule inhalers have a magazine from which individual capsules can be transferred to a receiving chamber, in which perforation and emptying takes place, as described in WO 92/03175.
  • Other capsule inhalers have revolving magazines with capsule chambers that can be brought in line with the air conduit for dose discharge (e. g. WO91/02558 and GB 2242134). They comprise the type of multiple unit dose inhalers together with blister inhalers, which have a limited number of unit doses in supply on a disk or on a strip.
  • Blister inhalers provide better moisture protection of the medicament than capsule inhalers. Access to the powder is obtained by perforating the cover as well as the blister foil, or by peeling off the cover foil.
  • a blister strip is used instead of a disk, the number of doses can be increased, but it is inconvenient for the patient to replace an empty strip. Therefore, such devices are often disposable with the incorporated dose system, including the technique used to transport the strip and open the blister pockets.
  • Multi-dose inhalers do not contain pre-measured quantities of the powder formulation. They consist of a relatively large container and a dose measuring principle that has to be operated by the patient. The container bears multiple doses that are isolated individually from the bulk of powder by volumetric displacement.
  • Various dose measuring principles exist, including rotatable membranes (e. g. EP0069715) or disks (e. g. GB 2041763; EP 0424790; DE 4239402 and EP 0674533), rotatable cylinders (e. g. EP 0166294; GB 2165159 and WO 92/09322) and rotatable frustums (e. g.
  • WO 92/00771 all having cavities which have to be filled with powder from the container.
  • Other multi dose devices have measuring slides (e. g. U.S. Pat. No. 5,201,308 and WO 97/00703) or measuring plungers with a local or circumferential recess to displace a certain volume of powder from the container to a delivery chamber or an air conduit e. g. EP 0505321, WO 92/04068 and WO 92/04928.
  • Reproducible dose measuring is one of the major concerns for multi dose inhaler devices.
  • the powder formulation has to exhibit good and stable flow properties, because filling of the dose measuring cups or cavities is mostly under the influence of the force of gravity.
  • the dose measuring accuracy and reproducibility can be guaranteed by the manufacturer.
  • Multi dose inhalers on the other hand, can contain a much higher number of doses, whereas the number of handlings to prime a dose is generally lower.
  • the inspiratory air stream in multi-dose devices is often straight across the dose measuring cavity, and because the massive and rigid dose measuring systems of multi dose inhalers can not be agitated by this inspiratory air stream, the powder mass is simply entrained from the cavity and little de-agglomeration is obtained during discharge.
  • the aclidinium is administered via a breath-activated, multidose, dry powder inhaler, calibrated to permit daily dosing of 400 ⁇ g metered nominal dose of aclidinium.
  • An especially preferred inhaler device for this purpose is Genuair®, (formerly known as Novolizer SD2FL), or as described in WO 97/000703, WO 03/000325, or WO 03/061742, the contents of which applications are incorporated herein by reference.
  • compositions of the invention can be administered in aerosols which operate via propellant gases or by means of so-called atomisers or nebulizers, via which solutions or suspensions of pharmacologically-active substances can be sprayed under high pressure so that a mist of inhalable particles results.
  • Medicaments for administration by inhalation desirably have a controlled particle size.
  • the optimum particle size for inhalation into the bronchial system is usually 1-10m, preferably 2-5 ⁇ m. Particles having a size above 20 ⁇ , are generally too large when inhaled to reach the small airways.
  • the particles of the active ingredient as produced may be size reduced by conventional means eg by micronisation or supercritical fluid techniques.
  • the desired fraction may be separated out by air classification or sieving.
  • the particles will be crystalline.
  • an excipient for example a mono-, di- or polysaccharide or sugar alcohol, e.g., such as lactose, mannitol or glucose is generally employed.
  • the particle size of the excipient will usually be much greater than the inhaled medicament within the present invention.
  • lactose particles When the excipient is lactose it will typically be present as lactose particles, preferably crystalline alpha lactose monohydrate, e.g., having an average particle size range of 20-1000 ⁇ m, preferably in the range of 90-150 ⁇ m.
  • the median particle size approximately corresponds to the average and is the diameter where 50 mass-% of the particles have a larger equivalent diameter, and the other 50 mass-% have a smaller equivalent diameter.
  • equivalent d50 The distribution of particle size around may affect flow properties, bulk density, etc.
  • other equivalent diameters can be used in addition to d50, such as d10 and d90.
  • d10 is the equivalent diameter where 10 mass-% of the particles have a smaller diameter (and hence the remaining 90% is coarser).
  • d90 is the equivalent diameter where 90 mass-% of the particles have a smaller diameter.
  • the lactose particles for use in formulations of the invention have a d10 of 90-160 ⁇ m, a d50 of 170-270 m, and d90 of 290-400 ⁇ m.
  • Suitable lactose materials for use in the present invention are commercially available, e.g., from DMW Internacional (Respitose GR-001, Respitose SV-001, Respitose SV-003); Meggle (Capsulac 60, Inhalac 70, Capsulac 60 INH); and Borculo Domo (Lactohale 100-200, Lactohale 200-300, and Lactohale 100-300).
  • the ratio between the lactose particles and the aclidinium by weight will depend on the inhaler device used, but is typically, e.g., 5:1 to 100:1, for example 25:1 to 75:1, e.g., 30-35:1.
  • the aclidinium is administered in the form of a dry powder formulation of aclidinium bromide in admixture with lactose, in a ratio by weight of aclidinium to lactose of 1:50 to 1:75, suitable for administration via a dry powder inhaler, wherein the aclidinium particles have an average particle size of from 2 to 5 ⁇ m in diameter, e.g., less than 3 ⁇ m in diameter, and the lactose particles have have a d10 of 90-160 ⁇ m, a d50 of 170-270 ⁇ m, and d90 of 290-400 ⁇ m.
  • Additional active agents such as ⁇ 2-agonists , PDE IV inhibitors, corticosteroids, leukotriene D4 antagonists, inhibitors of egfr-kinase, p38 kinase inhibitors or NK1 receptor agonists may be utilized in the methods and formulations of the inventions.
  • the invention provides aclidinium formulations as described herein further comprising an effective amount of one or more such additional active agents, e.g. further comprising an effective amount of a ⁇ 2-agonist and/or a PDE IV inhibitor and/or a corticosteroid.
  • the invention also provides methods for treating respiratory conditions as herein before described, e.g., asthma or COPD, comprising administering an aclidinium formulation as described herein and further comprising administering simultaneously an effective amount of one or more such additional active agents, e.g. further comprising an effective amount of a ⁇ 2-agonist and/or a PDE IV inhibitor and/or a corticosteroid.
  • ⁇ 2-agonists suitable for use with the aclidinium in the present invention include, e.g., arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaprotenerol, nolomirole, orciprenaline, pirbuterol, procaterol, reproterol, ritodrine, rimoterol, salbutamol, salmefamol, salmeterol, sibenadet, sotenerot, sulfonterol, terbutaline, tiaramide, tulobuterol, GSK-597901, milveterol, GSK-678007, GSK-6424
  • the preferred ⁇ 2-agonists to be used in the combinations of the invention are: arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, milveterol, LAS100977 (5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1
  • M3 antagonists of the invention have a long duration of action, it is preferred that they are combined with long-acting ⁇ 2-agonists (also known as LABAs).
  • LABAs long-acting ⁇ 2-agonists
  • LABAs are formoterol, salmeterol and GSK-597901, milveterol, LAS 100977 (5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one), KUL-1248, carmoterol and indacaterol optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts.
  • salmeterol formoterol
  • LAS 100977 (5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one), and indacaterol.
  • salmeterol, formoterol and LAS100977 (5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one), in particular salmeterol xinafoate, formoterol fumarate and LAS100977 (5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one).
  • the invention provides a pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt, e.g., bromide, in admixture with a pharmaceutically acceptable carrier, e.g., lactose particles, together with formoterol fumarate, (i) comprising a single metered nominal dose of aclidinium equivalent to about 400 ⁇ g aclidinium bromide together with a single metered nominal dose of about 5-25 ⁇ g (e.g.
  • composition for inhalation comprising aclidinium and a ⁇ 2-agonist, for example, formoterol or LAS100977 (5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one), can be administered one or more times per day. Preferably once or twice a day.
  • PDE4 inhibitors that can be combined with aclidinium in the present invention are benafentrine dimaleate, etazolate, denbufylline, rolipram, cipamfylline, zardaverine, arofylline, filaminast, tipelukast, tofimilast, piclamilast, tolafentrine, mesopram, drotaverine hydrochloride, lirimilast, roflumilast, cilomilast, oglemilast, apremilast, 6-[2-(3,4-Diethoxyphenyl)thiazol-4-yl]pyridine-2-carboxylic acid (tetomilast), (R)-(+)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine (CDP-840), N-(3,5-Dichloro-4-pyridine
  • corticosteroids and glucocorticoids that can be combined with aclidinium in the present invention are prednisolone, methylprednisolone, dexamethasone, dexamethasone cipecilate, naflocort, deflazacort, halopredone acetate, budesonide, beclomethasone dipropionate, hydrocortisone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, clocortolone pivalate, methylprednisolone aceponate, dexamethasone palmitoate, tipredane, hydrocortisone aceponate, prednicarbate, alclometasone dipropionate, Butixocort propionate, RPR-106541, halometasone, methylprednisolone suleptanate, mometasone furoate,
  • the invention provides a pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt, e.g., bromide, in admixture with a pharmaceutically acceptable carrier, e.g., lactose particles, together with mometasone furoate, (i) comprising a single metered nominal dose of aclidinium equivalent to about 400 ⁇ g aclidinium bromide together with a single metered nominal dose of about 100-900 ⁇ g (e.g.
  • composition for inhalation comprising aclidinium and a corticosteroid, for example mometasone furoate, can be administered one or more times per a day. Preferably once or twice a day.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising aclidinium, a ⁇ 2-agonist as defined above and a corticosteroid, as defined above.
  • a ⁇ 2-agonists are selected from LAS100977 ((5-(2- ⁇ [6-(2,2-difluoro-2-phenylethoxy)hexyl]amino ⁇ -1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one) and formoterol.
  • Most preferred corticosteroid is a mometasone furoate.
  • the ITT population included 460 patients. Aclidinium dose-dependently increased trough FEV 1 on Day 29 (table).
  • bronchodilatory effect of aclidinium during the first 6 h post-dose on Day 29 was comparable to that on Day 1 (all doses).
  • Time to peak FEV 1 was achieved at 3 h post-dose for aclidinium 100-400 ⁇ g.
  • Aclidinium was well tolerated, with no dose-dependent effect on ECG, laboratory parameters or adverse events.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/921,921 2008-03-13 2009-03-13 Novel dosage and formulation Abandoned US20110020412A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08382010A EP2100599A1 (en) 2008-03-13 2008-03-13 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP08382010.0 2008-03-13
PCT/EP2009/001832 WO2009112274A2 (en) 2008-03-13 2009-03-13 Novel dosage and formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/001832 A-371-Of-International WO2009112274A2 (en) 2008-03-13 2009-03-13 Novel dosage and formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/692,032 Continuation US10085974B2 (en) 2008-03-13 2012-12-03 Dosage and formulation

Publications (1)

Publication Number Publication Date
US20110020412A1 true US20110020412A1 (en) 2011-01-27

Family

ID=39645012

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/921,921 Abandoned US20110020412A1 (en) 2008-03-13 2009-03-13 Novel dosage and formulation
US13/692,032 Active US10085974B2 (en) 2008-03-13 2012-12-03 Dosage and formulation
US16/019,855 Active US11000517B2 (en) 2008-03-13 2018-06-27 Dosage and formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/692,032 Active US10085974B2 (en) 2008-03-13 2012-12-03 Dosage and formulation
US16/019,855 Active US11000517B2 (en) 2008-03-13 2018-06-27 Dosage and formulation

Country Status (37)

Country Link
US (3) US20110020412A1 (hr)
EP (5) EP2100599A1 (hr)
JP (3) JP2011513451A (hr)
KR (3) KR20180125055A (hr)
CN (2) CN104473911A (hr)
AR (1) AR070835A1 (hr)
AU (1) AU2009224895B9 (hr)
BR (1) BRPI0905775B1 (hr)
CA (1) CA2716724C (hr)
CL (1) CL2009000602A1 (hr)
CO (1) CO6290636A2 (hr)
CY (1) CY1116926T1 (hr)
DK (3) DK2265257T4 (hr)
EC (1) ECSP10010300A (hr)
ES (3) ES2551307T5 (hr)
FI (1) FI2265257T4 (hr)
HK (1) HK1145815A1 (hr)
HR (3) HRP20220929T3 (hr)
HU (3) HUE059020T2 (hr)
IL (3) IL206354A0 (hr)
LT (2) LT2954889T (hr)
ME (1) ME02286B (hr)
MX (2) MX368774B (hr)
MY (1) MY177027A (hr)
NZ (1) NZ585857A (hr)
PE (3) PE20141036A1 (hr)
PL (3) PL2954889T3 (hr)
PT (3) PT2954889T (hr)
RS (3) RS63398B1 (hr)
RU (3) RU2608713C3 (hr)
SG (1) SG188825A1 (hr)
SI (3) SI2954889T1 (hr)
TW (1) TWI439296B (hr)
UA (1) UA101652C2 (hr)
UY (1) UY31687A1 (hr)
WO (1) WO2009112274A2 (hr)
ZA (1) ZA201003900B (hr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299042A1 (en) * 2006-07-21 2009-12-03 Nuria Busquets Baque Process for manufacturing 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide
US20110020454A1 (en) * 2008-03-13 2011-01-27 Rosa Lamarca Casado Novel dosage and formulation
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2666465A1 (en) * 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
EA201590019A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
US20150202297A1 (en) * 2012-07-05 2015-07-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
PL2931275T3 (pl) 2012-12-17 2022-09-05 Almirall S.A. Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc
EP2991626A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
AU2015261239B2 (en) 2014-05-12 2020-02-27 Verona Pharma Plc New treatment
CZ2015257A3 (cs) * 2015-04-16 2016-10-26 Zentiva, K.S. Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu
CN107823193B (zh) * 2017-11-16 2021-02-05 广州迈达康医药科技有限公司 一种阿地溴铵吸入型粉雾剂及其制备方法

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US6620138B1 (en) * 1999-03-19 2003-09-16 Disetronic Licensing Ag Infusor, catheter means and catheter head
US6696042B2 (en) * 2001-03-08 2004-02-24 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20040266869A1 (en) * 2000-12-15 2004-12-30 Montague Christopher John Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005014005A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
WO2005115466A1 (en) * 2004-05-31 2005-12-08 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and corticosteroids
US20060252790A1 (en) * 2002-12-23 2006-11-09 Allen David G Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20110118223A1 (en) * 1999-07-14 2011-05-19 Maria Dolors Fernandez Forner Novel quinuclidine derivatives and medicinal compositions containing the same

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091570A (en) 1960-08-08 1963-05-28 Lakeside Lab Inc Antidepressant: 3-pyrrolidyl glycolates
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2414044A1 (fr) 1978-01-10 1979-08-03 Pharmindustrie Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8613811D0 (en) 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
US4675326A (en) 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US4843074A (en) 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ES2161211T3 (es) 1990-09-06 2001-12-01 Pfizer Broncodilatadores antimuscarinicos.
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
DE69132850T2 (de) 1990-09-26 2002-05-29 Pharmachemie B.V., Haarlem Wirbelkammer-Pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
US5865834A (en) 1991-12-13 1999-02-02 Mcguire; David A. Coring reamer
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
AU680227B2 (en) 1992-12-09 1997-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
AU683036B2 (en) 1992-12-18 1997-10-30 Merck Sharp & Dohme Corp. Inhaler for powdered medications
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5569447A (en) 1994-04-19 1996-10-29 The United States Of America Represented By The Secretary Department Of Health And Human Services Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives
EP0772656B1 (en) 1994-07-29 2001-03-21 Minnesota Mining And Manufacturing Company Acrylic syrup curable to a crosslinked viscoelastomeric material
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2206572T3 (es) 1995-04-14 2004-05-16 Smithkline Beecham Corporation Inhalador de dosis medida para salmeterol.
PL182198B1 (en) 1995-06-21 2001-11-30 Asta Medica Ag Pharmaceutic powder holding container with integrated measuring device and powdered
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (de) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg Neue Arzneimittel und ihre Verwendung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6423298B2 (en) 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
ATE253896T1 (de) 1998-06-18 2003-11-15 Boehringer Ingelheim Pharma Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19847968A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
FR2803378B1 (fr) 1999-12-29 2004-03-19 Valeo Climatisation Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile
CA2398199A1 (en) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
US6740655B2 (en) 2000-01-31 2004-05-25 Pfizer Inc Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
WO2001070746A1 (fr) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
GB0008485D0 (en) 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
WO2002013053A2 (en) 2000-08-10 2002-02-14 Eharmony.Com, Inc Method and system for identifying people who are likely to have a succesful relationship
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
WO2002036106A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
DE10056104A1 (de) 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DK1345937T3 (da) 2000-12-22 2006-01-16 Almirall Prodesfarma Ag Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
CZ301209B6 (cs) 2000-12-28 2009-12-09 Laboratorios Almirall, S.A. Nové chinuklidinové deriváty a medicinální kompozice s jejich obsahem
DE10104367A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20020189610A1 (en) 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
DE10104370A1 (de) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
CN1511042A (zh) 2001-05-25 2004-07-07 治疗阻塞性气道疾病的pde4抑制剂与抗胆碱能剂的组合
MXPA03010791A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
CA2459493C (en) 2001-09-14 2011-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions for inhalation
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
US6919325B2 (en) 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US6790856B2 (en) 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
PT3536344T (pt) 2002-03-01 2020-03-26 Chiesi Farm Spa Formulação superfina de formoterol
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7094788B2 (en) 2002-04-13 2006-08-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20130109244A (ko) 2002-05-17 2013-10-07 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006508996A (ja) 2002-11-27 2006-03-16 アルタナ ファルマ アクチエンゲゼルシャフト 悪液質の治療における使用のための、pde4及びpde3/4インヒビター
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
DK1610787T3 (da) 2003-03-28 2008-06-02 Nycomed Gmbh Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
WO2004084897A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20050026887A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
CA2534132C (en) 2003-07-29 2013-11-26 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic
US20050026886A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
CA2534125A1 (en) 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PT1713471E (pt) 2004-02-06 2012-04-10 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e inibidores de fosfodiesterase tipo 4 para o tratamento de doenças respiratórias
EP1713473B1 (en) 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
PL1718336T3 (pl) 2004-02-06 2008-11-28 Meda Pharma Gmbh & Co Kg Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego
ES2239546B1 (es) 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
RS50786B (sr) 2004-05-31 2010-08-31 Laboratorios Almirall S.A. Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergične agoniste
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
MX2009008794A (es) 2007-02-19 2009-08-25 Cipla Ltd Combinaciones farmaceuticas al menos de dos broncodilatadores o de un broncodilatador con un corticosteroide.
SI2120936T1 (sl) 2007-02-21 2011-10-28 Almirall Sa Novi postopki
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
PL2931275T3 (pl) 2012-12-17 2022-09-05 Almirall S.A. Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc
DK2936306T3 (da) 2012-12-21 2020-02-10 Intellipocket Oy Generering af en brugertilpasset anvendelse

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620138B1 (en) * 1999-03-19 2003-09-16 Disetronic Licensing Ag Infusor, catheter means and catheter head
US8129405B2 (en) * 1999-07-14 2012-03-06 Almirall Prodesfarma S.A. Quinuclidine derivatives and medicinal compositions containing the same
US20110118223A1 (en) * 1999-07-14 2011-05-19 Maria Dolors Fernandez Forner Novel quinuclidine derivatives and medicinal compositions containing the same
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
US6890517B2 (en) * 2000-10-31 2005-05-10 Boehringer Ingelheim Pharma Kg Inhalable formulation of a solution containing a tiotropium salt
US20040192675A1 (en) * 2000-10-31 2004-09-30 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20040176338A1 (en) * 2000-10-31 2004-09-09 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and corticosteroids
US20050147564A1 (en) * 2000-10-31 2005-07-07 Boehringer Ingelheim Pharma Kg Inhalable formulation of a solution containing a tiotropium salt
US20040266869A1 (en) * 2000-12-15 2004-12-30 Montague Christopher John Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
US20040161386A1 (en) * 2000-12-20 2004-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergic and dopamine agonists
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
US20040024007A1 (en) * 2001-03-07 2004-02-05 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US6696042B2 (en) * 2001-03-08 2004-02-24 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20040151770A1 (en) * 2001-03-08 2004-08-05 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20030203925A1 (en) * 2001-03-20 2003-10-30 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20060252790A1 (en) * 2002-12-23 2006-11-09 Allen David G Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
WO2005014005A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005115466A1 (en) * 2004-05-31 2005-12-08 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and corticosteroids

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US20090299042A1 (en) * 2006-07-21 2009-12-03 Nuria Busquets Baque Process for manufacturing 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide
US8044205B2 (en) 2006-07-21 2011-10-25 Laboratorios Almirall, S.A. Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide
US20110020454A1 (en) * 2008-03-13 2011-01-27 Rosa Lamarca Casado Novel dosage and formulation
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Also Published As

Publication number Publication date
PE20091672A1 (es) 2009-11-04
US20130189317A1 (en) 2013-07-25
EP2954890A1 (en) 2015-12-16
US10085974B2 (en) 2018-10-02
HRP20220929T3 (hr) 2022-10-28
IL271132A (en) 2020-01-30
ZA201003900B (en) 2011-04-28
JP2014139233A (ja) 2014-07-31
PL2265257T3 (pl) 2016-01-29
EP2954891B1 (en) 2022-05-04
US11000517B2 (en) 2021-05-11
AU2009224895B9 (en) 2015-07-30
LT2954891T (lt) 2022-06-10
SG188825A1 (en) 2013-04-30
EP2265257B1 (en) 2015-08-12
KR20180125055A (ko) 2018-11-21
RU2019100425A3 (hr) 2020-07-13
MX368774B (es) 2019-10-16
SI2265257T2 (sl) 2023-12-29
RU2010141333A (ru) 2012-04-20
EP2265257B2 (en) 2023-10-25
EP2954889A1 (en) 2015-12-16
PE20190406A1 (es) 2019-03-14
TW200938232A (en) 2009-09-16
ES2916831T3 (es) 2022-07-06
TWI439296B (zh) 2014-06-01
WO2009112274A3 (en) 2010-09-02
PT2265257E (pt) 2015-11-13
RS63399B1 (sr) 2022-08-31
ES2551307T3 (es) 2015-11-18
LT2954889T (lt) 2022-06-10
JP2016130248A (ja) 2016-07-21
EP2100599A1 (en) 2009-09-16
EP2265257A2 (en) 2010-12-29
PT2954891T (pt) 2022-05-19
CN102083416A (zh) 2011-06-01
CL2009000602A1 (es) 2010-03-12
ES2551307T5 (es) 2024-04-05
WO2009112274A2 (en) 2009-09-17
CO6290636A2 (es) 2011-06-20
MX2010008235A (es) 2010-08-10
CY1116926T1 (el) 2017-04-05
RS54241B1 (en) 2015-12-31
CN104473911A (zh) 2015-04-01
CA2716724C (en) 2016-04-26
DK2265257T4 (da) 2023-12-18
AU2009224895A1 (en) 2009-09-17
KR20200054329A (ko) 2020-05-19
DK2265257T3 (en) 2015-11-23
JP6170460B2 (ja) 2017-07-26
RU2019100425A (ru) 2020-07-13
UA101652C2 (uk) 2013-04-25
ES2914674T3 (es) 2022-06-15
EP2954889B1 (en) 2022-05-04
US20180303806A1 (en) 2018-10-25
PL2954891T3 (pl) 2022-09-26
NZ585857A (en) 2012-09-28
HUE059020T2 (hu) 2022-09-28
RU2014140674A (ru) 2016-04-27
SI2954891T1 (sl) 2022-07-29
ME02286B (me) 2016-02-20
PE20141036A1 (es) 2014-08-27
FI2265257T4 (fi) 2023-11-22
SI2265257T1 (sl) 2016-02-29
HRP20151214T4 (hr) 2024-01-05
KR20100126322A (ko) 2010-12-01
DK2954889T3 (da) 2022-06-07
HRP20220919T3 (hr) 2022-10-28
EP2954891A1 (en) 2015-12-16
AU2009224895B2 (en) 2015-07-02
DK2954891T3 (da) 2022-06-13
PT2954889T (pt) 2022-05-19
PL2265257T5 (pl) 2024-06-10
JP2011513451A (ja) 2011-04-28
RU2608713C3 (ru) 2018-09-10
CA2716724A1 (en) 2009-09-17
ECSP10010300A (es) 2010-07-30
AR070835A1 (es) 2010-05-05
HUE027726T2 (en) 2016-11-28
BRPI0905775B1 (pt) 2021-07-27
MY177027A (en) 2020-09-02
BRPI0905775A2 (pt) 2018-05-22
IL249072A0 (en) 2017-01-31
SI2954889T1 (sl) 2022-07-29
HK1145815A1 (zh) 2011-05-06
RS63398B1 (sr) 2022-08-31
PL2954889T3 (pl) 2022-11-07
HUE059019T2 (hu) 2022-09-28
UY31687A1 (es) 2009-08-31
RU2608713C2 (ru) 2017-01-23
HRP20151214T1 (hr) 2015-12-18
IL206354A0 (en) 2010-12-30
RS54241B2 (sr) 2024-02-29

Similar Documents

Publication Publication Date Title
US11000517B2 (en) Dosage and formulation
US9254262B2 (en) Dosage and formulation
AU2013265167B2 (en) Novel dosage and formulation
AU2009224894B8 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALMIRALL, S.A., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAMARCA CASADO, ROSA;DE MIQUEL SERRA, GONZALO;SIGNING DATES FROM 20100917 TO 20100920;REEL/FRAME:025093/0703

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION